Alessandro Giunta

Alessandro Giunta

Auto-generated profile, based on publicly available information

Alessandro Giunta

Department of Dermatology, University of Rome Tor Vergata, Rome, Italy

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2009 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
DPD Pathirana
D Pathirana
AOAd Ormerod
Ad Ormerod
PSP Saiag
P Saiag
CSC Smith
C Smith
PSPi Spuls
Pi Spuls
BRB Rzany
B Rzany
Of the 131 studies on monotherapy or combination therapy assessed, 56 studies on the different forms of phototherapy fulfilled the criteria for inclusion in the guidelines. Approximately three-quarters of all patients treated with phototherapy attained at least a PASI 75 response after 4 to 6 weeks, and clearance was frequently achieved (levels of evidence 2 and 3). Phototherapy represents a safe and very effective treatment option for moderate to severe forms of psoriasis vulgaris. The onset of clinical effects occurs within 2 weeks. Of the unwanted side effects, UV erythema from overexposure is by far the most common and is observed frequently. With repeated or long-term use, the consequences of high, cumulative UV doses (such as premature aging of the skin) must be taken into consideration. In addition, carcinogenic risk is associated with oral PUVA and is probable for local PUVA and UVB. The practicability of the therapy is limited by spatial, financial, human, and time constraints on the part of the physician, as well as by the amount of time required by the patient. From the perspective of the cost-bearing institution, phototherapy has a good cost-benefit ratio. However, the potentially significant costs for, and time required of, the patient must be considered.

1 February 2006 in Dermatology
Verified
Journal Article
Closed access
MEMaria Esposito
Maria Esposito
RSRosita Saraceno
Rosita Saraceno
AGAlessandro Giunta
Alessandro Giunta
MMMara Maccarone
Mara Maccarone
SCSergio Chimenti
Sergio Chimenti
Background: Psoriasis is often associated with the risk of physical disability, social discomfort and psychological disorders. Objectives: The aim of this study was to investigate the prevalence of depressive symptomatology among Italian patients with psoriasis vulgaris, in order to better evaluate the disease severity in this patient population. Methods: Five thousand Italian patients with psoriasis were mailed the Center for Epidemiological Studies-Depression Scale (CES-D) questionnaire, a 20-item instrument developed to perform epidemiological studies of depressive symptomatology in the general population. Questionnaires with responses to 16 or more items were considered evaluable. Results: We received evaluable questionnaires from 2,391 patients, including 1,528 men (63.9%) and 863 women (36.1%). Depressive symptomatology was observed in 1,482/2,391 patients (62% overall; females, 63%; males, 61%). Men <40 years of age were significantly more likely to report depressive symptoms than were men ≧40 years of age (67 vs. 58%, respectively; p = 0.002). Depressive symptomatology was more prevalent in psoriatic patients with only primary or secondary education than in psoriatic patients with higher education (51 vs. 32%, respectively; p < 0.02). Conclusion: Our results are consistent with previous studies showing that psoriasis is associated with profound psychological morbidity, in particular with depression in a large number of patients. It is important to consider this association in the overall management of psoriasis.

3 May 2010 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
FMFrancesca Moretti
Francesca Moretti
BMBarbara Marinari
Barbara Marinari
NINadia Lo Iacono
Nadia Lo Iacono
EBElisabetta Botti
Elisabetta Botti
AGAlessandro Giunta
Alessandro Giunta
ACAntonio Costanzo
Antonio Costanzo
The human congenital syndromes ectrodactyly ectodermal dysplasia-cleft lip/palate syndrome, ankyloblepharon ectodermal dysplasia clefting, and split-hand/foot malformation are all characterized by ectodermal dysplasia, limb malformations, and cleft lip/palate. These phenotypic features are a result of an imbalance between the proliferation and differentiation of precursor cells during development of ectoderm-derived structures. Mutations in the p63 and interferon regulatory factor 6 (IRF6) genes have been found in human patients with these syndromes, consistent with phenotypes. Here, we used human and mouse primary keratinocytes and mouse models to investigate the role of p63 and IRF6 in proliferation and differentiation. We report that the ΔNp63 isoform of p63 activated transcription of IRF6, and this, in turn, induced proteasome-mediated ΔNp63 degradation. This feedback regulatory loop allowed keratinocytes to exit the cell cycle, thereby limiting their ability to proliferate. Importantly, mutations in either p63 or IRF6 resulted in disruption of this regulatory loop: p63 mutations causing ectodermal dysplasias were unable to activate IRF6 transcription, and mice with mutated or null p63 showed reduced Irf6 expression in their palate and ectoderm. These results identify what we believe to be a novel mechanism that regulates the proliferation-differentiation balance of keratinocytes essential for palate fusion and skin differentiation and links the pathogenesis of 2 genetically different groups of ectodermal dysplasia syndromes into a common molecular pathway.

30 August 2013 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
MEMaria Esposito
Maria Esposito
PGPaolo Gisondi
Paolo Gisondi
NCN. Cassano
N. Cassano
GFG. Ferrucci
G. Ferrucci
MGM. Del Giglio
M. Del Giglio
GGG. Girolomoni
G. Girolomoni

1 August 2007 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
MPMarina Papoutsaki
Marina Papoutsaki
MCMaria Sole Chimenti
Maria Sole Chimenti
ACAntonio Costanzo
Antonio Costanzo
MTMarina Talamonti
Marina Talamonti
AZArianna Zangrilli
Arianna Zangrilli
SCSergio Chimenti
Sergio Chimenti

28 December 2012 in Dermatology
Verified
Journal Article
Open access
PDF file
MEMaria Esposito
Maria Esposito
AGAlessandro Giunta
Alessandro Giunta
AMAnnamaria Mazzotta
Annamaria Mazzotta
AZArianna Zangrilli
Arianna Zangrilli
GBGraziella Babino
Graziella Babino
MCMaria Sole Chimenti
Maria Sole Chimenti
Background: In elderly patients the management of psoriasis is challenging due to contraindications and a higher risk of side effects. Objective: Our retrospective study aimed to evaluate the long-term efficacy and safety profile of subcutaneous anti-tumor necrosis factor (anti-TNF) agents in elderly psoriatic patients. Methods: The study included 89 patients (aged ≥65 years) with plaque-type psoriasis and psoriatic arthritis treated with the subcutaneous anti-TNF-α agents etanercept or adalimumab as monotherapy for a long-term continuous period. Results: Efficacy results were consistent and stable over long-term observation, as expressed by mean Psoriasis Area and Severity Index (PASI) score variation, percentage of patients achieving PASI50 and PASI75 and by the improvement of articular indices, pain visual analogue scale (Pain-VAS) and 44-Joint Disease Activity Score (DAS44-ESR). The proportion of patients achieving PASI50 was 91.80 and 82.14% at week 156 with etanercept and adalimumab treatment, respectively, while the proportion of patients achieving PASI75 was 83.61 and 71.43% at week 156 when treated with etanercept and adalimumab, respectively. The mean DAS44-ESR score decreased from 5.80 to 0.89 and from 3.43 to 1.44 at week 156 and the mean Pain-VAS score decreased from 75.10 to 3.15 and from 71.30 to 18.26 at week 156 with etanercept and adalimumab treatment, respectively. Both treatment adherence and safety profile were good. Conclusions: Our study demonstrates that subcutaneous anti-TNF-α agents are appropriate in the long-term management of elderly patients.